



August 29, 2018

**The General Manager (Department of Corporate Services)
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001**

Dear Sir,

Sub: Rejoinder of Q 1 results and corrected version - Clause 41 of listing agreement

We apologise for a typographical error in our earlier sent unaudited results dated 14th August 2018 for the quarter ending 30th June 2018. The corrected version is attached herein and to be uploaded accordingly.

This is to bring to your kind notice.

Thanking you,

Yours sincerely,

For **TRANSGENE BIOTEK LIMITED**

A handwritten signature in black ink, appearing to read "Dr. K. K. Rao", is positioned above the printed name and title.

**Dr. K. K. Rao
MANAGING DIRECTOR**



Statement of standalone unaudited financial results for the quarter ended 30th June 2018

(Amount in Rs.)

S.No.	Particulars	3 months ended 30.06.2018 (Unaudited)	Preceding 3 months ended 31.03.2018 (Unaudited)	Corresponding 3 months ended in the previous year 30.06.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
1 INCOME					
i	Revenue from operations	712,870	-29,059	-	1,182,406
ii	Other income	438,470	72,361,118	492,470	73,726,947
	Total income (i+ii)	1,151,340	72,332,059	492,470	74,909,353
2 EXPENSES					
i.	Cost of materials consumed	-1,476	235,427	-	347,382
ii.	Changes in inventories of finished goods and work-in-progress	-	139,715	-	139,715
iii.	Employee benefits expense	460,811	349,166	800,258	3,276,852
iv.	Finance cost	-	1,410,232	691,750	10,281,689
v.	Depreciation and amortisation expense	24,723,250	24,704,016	24,736,799	98,914,413
vi.	Other expenses	849,056	16,387,313	549,826	18,471,754
	Total expenses	26,031,641	43,225,869	26,778,633	131,431,805
3	Profit/ (Loss) before exceptional items & tax (3-4)	-24,880,301	29,106,190	-26,286,163	-56,522,452
4	Exceptional items	-	-	-	-
5	Profit/ (Loss) before tax (5+ 6)	-24,880,301	29,106,190	-26,286,163	-56,522,452
6	Tax expense (including deferred tax).	-	-	-	-
7	Prior Period Taxes	-	-	-	7,860,849
8	Profit/(Loss) for the period (7 - 8)	-24,880,301	29,106,190	-26,286,163	-64,383,301
9	Other comprehensive income / (Loss) (net of tax)	262	198	4,543	1,860
10	Total comprehensive income / (Loss) for the period (9+10)	-24,880,039	29,106,388	-26,281,620	-64,381,441
11	Paid-up equity share capital (Face value of ₹ 10/- each) (Refer Note 4)	757,700,000	757,700,000	757,700,000	757,700,000
12	Other equity excluding revaluation reserves	-	-	-	-
13	Earnings per share Basic and diluted (₹) (not annualised)	-0.03	0.04	-0.03	-0.08

As required under clause 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Statutory Auditors have conducted a limited review of the above financial results for the quarter ended 30th June 2018.

The above statement of financial results are approved by the Board of Directors at the Meeting held on 14th August 2018.

The previous period figures have been regrouped and reclassified wherever necessary to make them comparable with current period figures.

The Company is operating in only one segment of Bulk Drugs, hence Segment Wise Report is not applicable as per IND AS 108.

These results have been prepared in accordance with the Ind AS notified under the companies (Indian Accounting Standards) Rules 2015, as amended.

Adoption of Ind AS 115-Revenue from Contract with customers :

Effective April 1,2018, the company has adopted Ind AS 115 "Revenue from Contract with Customers" using the cumulative effect method. The standard is applied retrospectively only to contracts that are not completed as at the date of initial application and hence the comparative information is not restated.

For and on behalf of Board of Directors

Place : Hyderabad
Date: 14 August 2018

Chairman and Managing Director